fda glp-1 warning news november 2025 Societies take stand against off-brand GLP-1s over safety concerns Covering GLP-1 Drugs: Employers' Top

Patients with pre-existing diabetic retinopathy should be monitored closely, as rapid improvement in blood glucose control may temporarily worsen retinopathy

The SURMOUNT-1 trial tested the ability of tirzepatide to produce weight loss in people with obesity who do not have diabetes

Read Ipsos latest PoV, where we explore these topics in more depth: Ipsos has tracked MASH treatment since 2017

24 weeks 24 syringes 1 syringe per weekly injection

Glucagon-Like Peptide-1 and Its Class B G ProteinCoupled Receptors: a Long March to Therapeutic Successes

Available from: Linda Gigliotti 1 , Hope Warshaw 2 , Alison Evert 3 , Colleen Dawkins 4 , Julie Schwartz 5 , Caroline Susie 6 , Robert Kushner 7 , Savitha Subramanian 8 , Deepa Handu 9 , Mary Rozga 10 Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care